Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a Web-based dashboard for providers; PhreesiaPads, which are self-service intake tablets; and Arrivals Kiosks that are on-site kiosks. Its Phreesia Platform also provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; appointments solution for online appointments, reminders, and referral tracking; and patient activation solution that enables providers to communicate with their patients through surveys, announcements, messaging, and health campaigns. In addition, the company's Phreesia Platform offers clinical support solution, which collects clinical intake and PRO data for approximately 25 specialties; and life sciences solution to deliver targeted and clinically relevant marketing content to patients, as well as COVID-19 product offerings for managing COVID-19 vaccine delivery and identify vaccine-hesitant patients, screening for self-reported COVID-19 risk factors, enabling contactless check-in during in-person visits, and collecting intake information during telehealth visits. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was founded in 2005 and is headquartered in Raleigh, North Carolina.
IPO Year: 2019
Exchange: NYSE
Website: phreesia.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/8/2025 | $24.00 → $32.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 2/26/2024 | $35.00 | Buy | Truist |
| 1/17/2024 | $30.00 → $32.00 | Neutral → Buy | DA Davidson |
| 1/3/2024 | $29.00 | Overweight | Barclays |
| 4/12/2023 | $37.00 | Overweight | Stephens |
| 1/4/2023 | $35.00 → $40.00 | Buy | Needham |
| 12/13/2022 | $40.00 | Neutral → Buy | Citigroup |
| 12/9/2022 | $31.00 → $34.00 | Mkt Perform → Outperform | SVB Leerink |
| 10/13/2022 | $25.00 | Neutral | DA Davidson |
| 9/16/2022 | $40.00 | Overweight | KeyBanc Capital Markets |
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
SC 13G/A - Phreesia, Inc. (0001412408) (Subject)
SC 13G/A - Phreesia, Inc. (0001412408) (Subject)
SC 13G/A - Phreesia, Inc. (0001412408) (Subject)
SC 13G - Phreesia, Inc. (0001412408) (Subject)
SC 13G/A - Phreesia, Inc. (0001412408) (Subject)
SC 13G/A - Phreesia, Inc. (0001412408) (Subject)
SC 13G/A - Phreesia, Inc. (0001412408) (Subject)
SC 13G/A - Phreesia, Inc. (0001412408) (Subject)
SC 13G - Phreesia, Inc. (0001412408) (Subject)
SC 13G/A - Phreesia, Inc. (0001412408) (Subject)
Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal third quarter ended October 31, 2024. "We are excited about the future here at Phreesia," said CEO and Co-Founder Chaim Indig. "Our network continues to grow, adoption of our current offerings is increasing, and we are beginning to see the promise of new solutions we are investing in." Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q3 Fiscal Year 2025 Stakeholder Letter. Fiscal Third Quarter Ended October 31, 2024 Highlights Total revenue was $106.8 million in the quarter, up 17% year-over-year. Average number of healthcare servi
Phreesia, a leader in patient intake, outreach and activation, has been selected by The Software Report as one of the "Top 100 Software Companies of 2024." The annual program evaluates companies based on a range of criteria, including product functionality, customer satisfaction, corporate reputation, innovative capabilities, organizational depth, ESG involvement and long-term viability. This is the third consecutive year Phreesia has been named to the list. "We are proud once again to be recognized as a leader in SaaS innovation," said Phreesia CEO Chaim Indig. "This honor reflects Phreesia's dedication to investing in products that help drive better health outcomes. We remain committed
Phreesia, Inc. (NYSE:PHR) ("Phreesia") today announced that it will release its fiscal third quarter 2025 financial results after the close of market trading on Monday, Dec. 9, 2024. Phreesia will issue a press release announcing its quarterly results and the company's quarterly stakeholder letter, both of which will be posted on its investor website at ir.phreesia.com. Phreesia will then hold a conference call to discuss its fiscal third quarter results starting at 5PM Eastern Time on the same day. To participate in the company's live conference call and webcast, please dial (800) 715-9871, or (646) 307-1963 for international participants, using conference code number 7404611, or visit th
Phreesia, a leader in patient intake, outreach and activation, and a member of Oracle PartnerNetwork (OPN), today announced that it has achieved Oracle Validated Integration with Oracle Health Electronic Health Record (EHR) Expertise for its integration of the Phreesia platform. Phreesia gives clients a suite of tools to manage patient intake across care settings and service lines. Its logic-driven tools enable healthcare organizations to operate more efficiently and provide a high-quality patient experience at scale. Expertise is a core tenet of the Oracle PartnerNetwork (OPN) program and allows Oracle partners to highlight their capabilities in a focused area. Ultimately, Expertise is de
Phreesia will work with the NAI to shape the national conversation around data privacy and promote consumer choice and transparency As part of the company's ongoing commitment to consumer data privacy, Phreesia is pleased to announce it has joined the Network Advertising Initiative (NAI), a non–profit organization and the leading self-regulatory association dedicated to responsible data collection and use for digital advertising. As a member, Phreesia will work with the NAI to promote consumer-centric privacy practices in healthcare and take a leadership role in shaping the national conversation around data privacy. "We are excited to join the NAI, an organization that shares our dedicati
Messaging at the point of care encourages patients to take steps toward improving their mental health Phreesia, a leader in patient intake, outreach and activation, has collaborated with the Ad Council, a nonprofit organization at the forefront of driving change through social impact marketing, to bring three public health campaigns about mental health directly to patients and caregivers. Collectively across the campaigns, Phreesia has already delivered more than 430,000 messages, helping to spread awareness about the importance of youth and adult mental wellbeing and encouraging more open conversations about mental health. Key Phreesia findings among patients and caregivers who consented
Phreesia, a leader in patient intake, outreach and activation, is pleased to announce that its contract with the CMS Innovation Center (CMMI) for use of the Patient Activation Measure® (PAM) has been renewed through 2029. The PAM performance measure, which assesses gains in patients' knowledge, skills and confidence in managing their own healthcare, is one of the first patient-reported outcome performance measures (PRO-PMs) used in a CMS alternative payment model. Under the new contract, Phreesia will provide access to PAM, training, analysis and other support to the Kidney Care Choices Model (KCC). CMMI also has the option to expand the PAM into additional models, including those focused o
Findings reveal that delivering digital, vaccine-related messages before medical appointments more than doubles the rate of vaccine uptake. New Phreesia research examining more than 20.2 million digital vaccine messages indicates that providing adults and caregivers with vaccine information just before their appointments, or at the point of care, is an effective strategy for supporting vaccine confidence and adoption, including among historically marginalized populations. Between March 2020 and May 2024, Phreesia delivered vaccine messages to patients in all 50 states, just before appointments in various care settings. Patients were segmented into subpopulations based on demographics, vac
Phreesia, a leader in patient intake, outreach and activation, together with the National Association For Continence (NAFC), Health.Equity.Outcomes. and Christina Escobar, MD, at New York University, are proud to announce that the U.S. Centers for Disease Control and Prevention (CDC) has awarded a research grant for a joint project focused on combating the public health challenge of urinary incontinence (UI) in women. This grant will fund a campaign to raise awareness of UI, which affects nearly 100 million women in the U.S. but remains underdiagnosed, undertreated and underdiscussed. Deployed on Phreesia's digital patient engagement platform, the campaign will aim to empower women to star
Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal second quarter ended July 31, 2024. "We reached another very important milestone in Phreesia's evolution by crossing over to positive Free cash flow1 in the fiscal second quarter of 2025," said CEO and Co-Founder Chaim Indig. "We believe this milestone marks the start of a new era for Phreesia in which we are able to deploy internally generated cash to drive stakeholder value." Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q2 Fiscal Year 2025 Stakeholder Letter. Fiscal Second Quarter Ended July 31, 2024 Highlights Total revenue was
144 - Phreesia, Inc. (0001412408) (Subject)
144 - Phreesia, Inc. (0001412408) (Subject)
144 - Phreesia, Inc. (0001412408) (Subject)
144 - Phreesia, Inc. (0001412408) (Subject)
144 - Phreesia, Inc. (0001412408) (Subject)
144 - Phreesia, Inc. (0001412408) (Subject)
10-Q - Phreesia, Inc. (0001412408) (Filer)
8-K - Phreesia, Inc. (0001412408) (Filer)
10-Q - Phreesia, Inc. (0001412408) (Filer)
8-K - Phreesia, Inc. (0001412408) (Filer)
RBC Capital Mkts upgraded Phreesia from Sector Perform to Outperform and set a new price target of $32.00 from $24.00 previously
Truist initiated coverage of Phreesia with a rating of Buy and set a new price target of $35.00
DA Davidson upgraded Phreesia from Neutral to Buy and set a new price target of $32.00 from $30.00 previously
Barclays initiated coverage of Phreesia with a rating of Overweight and set a new price target of $29.00
Stephens initiated coverage of Phreesia with a rating of Overweight and set a new price target of $37.00
Needham reiterated coverage of Phreesia with a rating of Buy and set a new price target of $40.00 from $35.00 previously
Citigroup upgraded Phreesia from Neutral to Buy and set a new price target of $40.00
SVB Leerink upgraded Phreesia from Mkt Perform to Outperform and set a new price target of $34.00 from $31.00 previously
DA Davidson initiated coverage of Phreesia with a rating of Neutral and set a new price target of $25.00
KeyBanc Capital Markets initiated coverage of Phreesia with a rating of Overweight and set a new price target of $40.00
Phreesia will work with the NAI to shape the national conversation around data privacy and promote consumer choice and transparency As part of the company's ongoing commitment to consumer data privacy, Phreesia is pleased to announce it has joined the Network Advertising Initiative (NAI), a non–profit organization and the leading self-regulatory association dedicated to responsible data collection and use for digital advertising. As a member, Phreesia will work with the NAI to promote consumer-centric privacy practices in healthcare and take a leadership role in shaping the national conversation around data privacy. "We are excited to join the NAI, an organization that shares our dedicati
Phreesia, a leader in patient intake, outreach and activation, is proud to announce that Audrey Gato, Vice President of Client Solutions, has been named to The Software Report's list of the Top 50 Women Leaders in SaaS of 2023. Honorees were chosen based on their leadership and contributions to the Software-as-a-Service industry. This is the sixth consecutive year a female leader from Phreesia has been named to the list. Previous Phreesia awardees include Allison Hoffman, General Counsel; Kristin Roberts, Vice President of Product Management; Kharen Hauck, Vice President of Marketing; Amy VanDuyn, Senior Vice President of Human Resources; and Sara DiNardo, Vice President of Client Solutio
Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal third quarter ended October 31, 2024. "We are excited about the future here at Phreesia," said CEO and Co-Founder Chaim Indig. "Our network continues to grow, adoption of our current offerings is increasing, and we are beginning to see the promise of new solutions we are investing in." Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q3 Fiscal Year 2025 Stakeholder Letter. Fiscal Third Quarter Ended October 31, 2024 Highlights Total revenue was $106.8 million in the quarter, up 17% year-over-year. Average number of healthcare servi
Phreesia, Inc. (NYSE:PHR) ("Phreesia") today announced that it will release its fiscal third quarter 2025 financial results after the close of market trading on Monday, Dec. 9, 2024. Phreesia will issue a press release announcing its quarterly results and the company's quarterly stakeholder letter, both of which will be posted on its investor website at ir.phreesia.com. Phreesia will then hold a conference call to discuss its fiscal third quarter results starting at 5PM Eastern Time on the same day. To participate in the company's live conference call and webcast, please dial (800) 715-9871, or (646) 307-1963 for international participants, using conference code number 7404611, or visit th
Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal second quarter ended July 31, 2024. "We reached another very important milestone in Phreesia's evolution by crossing over to positive Free cash flow1 in the fiscal second quarter of 2025," said CEO and Co-Founder Chaim Indig. "We believe this milestone marks the start of a new era for Phreesia in which we are able to deploy internally generated cash to drive stakeholder value." Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q2 Fiscal Year 2025 Stakeholder Letter. Fiscal Second Quarter Ended July 31, 2024 Highlights Total revenue was
Phreesia, Inc. (NYSE:PHR) ("Phreesia") today announced that it will release its fiscal second quarter 2025 financial results after the close of market trading on Wednesday, Sept. 4, 2024. Phreesia will issue a press release announcing its quarterly results and the company's quarterly stakeholder letter, both of which will be posted on its investor website at ir.phreesia.com. Phreesia will then hold a conference call to discuss its fiscal second quarter results starting at 5PM Eastern Time on the same day. To participate in the company's live conference call and webcast, please dial (800) 715-9871, or (646) 307-1963 for international participants, using conference code number 7404611, or v
Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal first quarter ended April 30, 2024. "I am tremendously proud of our team's commitment to our growth and profitability1 objectives." said CEO and Co-Founder Chaim Indig. Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q1 Fiscal Year 2025 Stakeholder Letter. Fiscal First Quarter Ended April 30, 2024 Highlights Total revenue was $101.2 million in the quarter, up 21% year-over-year. Average number of healthcare services clients ("AHSCs") was 4,065 in the quarter, up 23% year-over-year. Healthcare services revenue per AHSC was $18
Phreesia, Inc. (NYSE:PHR) ("Phreesia") today announced that it will release its fiscal first quarter 2025 financial results after the close of market trading on Thursday, May 30, 2024. Phreesia will issue a press release announcing its quarterly results and the company's quarterly stakeholder letter, both of which will be posted on its investor website at ir.phreesia.com. Phreesia will then hold a conference call to discuss its fiscal first quarter results starting at 5PM Eastern Time on the same day. To participate in the company's live conference call and webcast, please dial (888) 350-3437, or (646) 960-0153 for international participants, using conference code number 4000153, or visit
Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal fourth quarter and fiscal year ended January 31, 2024. "Phreesia ended fiscal year 2024 with strong momentum going into fiscal 2025. We facilitated more than 150 million patient visits in fiscal 2024, or more than one in ten patient visits across the U.S. We are confident that our solutions and our team position us for continued growth and a return to profitability1," said CEO and Co-Founder Chaim Indig. Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q4 Fiscal Year 2024 Stakeholder Letter. Fiscal Fourth Quarter Ended January 31, 2024 H
Phreesia, Inc. (NYSE:PHR) ("Phreesia") today announced that it will release its fiscal fourth quarter 2024 financial results after the close of market trading on Thursday, March 14, 2024. Phreesia will issue a press release announcing its quarterly results and the company's quarterly stakeholder letter, both of which will be posted on its investor website at ir.phreesia.com. Phreesia will then hold a conference call to discuss its fiscal fourth quarter results starting at 5PM Eastern Time on the same day. To participate in the company's live conference call and webcast, please dial (888) 350-3437, or (646) 960-0153 for international participants, using conference code number 4000153, or v
Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal third quarter ended October 31, 2023. "I am proud of our work during the third quarter to further our mission of helping patients take a more active role in their care," said CEO and Co-Founder Chaim Indig. Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q3 Fiscal Year 2024 Stakeholder Letter. Fiscal Third Quarter Ended October 31, 2023 Highlights Total revenue was $91.6 million in the quarter as compared to $73.1 million in the same period in the prior year, an increase of 25%. Average number of healthcare services clients ("AHSC
Phreesia, Inc. (NYSE:PHR) ("Phreesia") today announced that it will release its fiscal third quarter 2024 financial results after the close of market trading on Tuesday, December 5, 2023. Phreesia will issue a press release announcing its quarterly results and the company's quarterly stakeholder letter, both of which will be posted on its investor website at ir.phreesia.com. Phreesia will then hold a conference call to discuss its fiscal third quarter results starting at 5PM Eastern Time on the same day. To participate in the company's live conference call and webcast, please dial (888) 350-3437, or (646) 960-0153 for international participants, using conference code number 4000153, or vi